Private Capital Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Private Capital Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Hold	8	–	–	﹤0.01%	1653
2022 Q1	$1K	Hold	8	–	–	﹤0.01%	1892
2021 Q4	$1K	Hold	8	–	–	﹤0.01%	1896
2021 Q3	$2K	Hold	8	–	–	﹤0.01%	1817
2021 Q2	$1K	Hold	8	–	–	﹤0.01%	1940
2021 Q1	$1K	Hold	8	–	–	﹤0.01%	1842
2020 Q4	$1K	Hold	8	–	–	﹤0.01%	1860
2020 Q3	$1K	Hold	8	–	–	﹤0.01%	1802
2020 Q2	$1K	Buy	+8	New	+$1.08K	﹤0.01%	1791
2019 Q2	–	Sell	-16	Closed	-$1K	–	2206
2019 Q1	$1K	Hold	16	–	–	﹤0.01%	1989
2018 Q4	$1K	Buy	16 +2	+14%	+$154	﹤0.01%	1988
2018 Q3	$1K	Buy	+14	New	+$1.41K	﹤0.01%	2023

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Private Capital Group's ALNY Position: Q2 2022 in Review

Private Capital Group held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2022 at 8 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1653.

Private Capital Group first reported a position in ALNY in Q3 2018 and has held it in 12 quarters since. The position peaked at $2K in Q3 2021. 422 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

Private Capital Group held 8 shares of Alnylam Pharmaceuticals worth $1K as of Q2 2022.
Private Capital Group left its Alnylam Pharmaceuticals share count unchanged in Q2 2022.
Alnylam Pharmaceuticals made up ﹤0.01% of Private Capital Group's portfolio in Q2 2022, its #1653 holding.
Private Capital Group first reported a position in Alnylam Pharmaceuticals in Q3 2018 and has held it in 12 quarters since.
Private Capital Group's Alnylam Pharmaceuticals position peaked at $2K in Q3 2021.
422 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.